Procaine

As a classic local anesthetic that has been in clinical application for more than a hundred years, procaine is an ester local anesthetic. It exerts local anesthetic effect by reversibly blocking sodium channels on the nerve cell membrane and inhibiting the generation and conduction of nerve impulses. With weak anesthetic efficacy, short duration of action and poor mucosal penetration, it is mainly used clinically for infiltration anesthesia, block anesthesia, lumbar anesthesia, epidural anesthesia, block therapy and so on. The applicable population covers patients of all ages requiring local anesthesia procedures. Due to its few adverse reactions and fast metabolism rate, it is still a commonly used local anesthetic option in primary medical scenarios up to now.

At present, the global market size of local anesthetics has exceeded 8 billion US dollars, with a compound annual growth rate maintained at around 4.5%, among which ester local anesthetics account for about 12% of the overall local anesthetic market. As a basic local anesthetic variety, procaine has stable market demand. Its global production capacity is mainly concentrated in generic drug manufacturing countries such as China and India. The annual terminal sales in domestic public medical institutions exceed 300 million yuan, and the price drop after centralized procurement has reached 62%. The market competition is dominated by generic pharmaceutical enterprises, and the top 3 enterprises occupy nearly 70% of the domestic market share.

The original developer of procaine is Bayer AG of Germany, and the original brand name is Novocain. Its core compound patent expired in the 1940s. Currently, the procaine preparations marketed in China are mainly procaine hydrochloride injections, with common specifications including 2ml:40mg, 10ml:100mg, etc., which have been included in the *Catalog of Reference Preparations for Chemical Drugs* issued by the National Medical Products Administration. Up to now, there have been 32 CDE registration numbers for procaine hydrochloride active pharmaceutical ingredients (APIs) in China, 21 of which are in status A and can be used for associated preparation declaration. More than 140 enterprises have obtained approval for domestic procaine hydrochloride injections. (Data as of April 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of procaine impurity reference standards, most of which are in stock. In-stock products ordered before 16:00 will be shipped on the same day. They meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the reference standard use needs of the whole process including API R&D, quality research, registration and declaration, etc.